摘要
Abstract
Objective:To compare the difference of clinical efficacy between BCH-2003 program and CCLG-2008 regimen in the diagnosis of acute lymphoblastic leukemia(molecular marker TEL-AML1),so as to provide reference for clinical children to choose appropriate diagnosis and treatment plan according to the actual condition. Methods:From August 2012 to December 2015,120 cases of children with acute lympho-blastic leukemia who were hospitalized for chemotherapy in our hospital were enrolled in the study. They were treated by BCH-2003 program and CCLG-2008 program. The children in each group were 60 cases,respec-tively. The molecular biological markers were TEL-AML1. The statistical differences in the recurrence of the two groups,the plasma related biochemical indexes(VEGF,VEGFR,bFGF,MVD),and the clinical effica-cy were compared. Results:The changes of VEGF,VEGFR,bFGF and MVD were significantly changed (P<0.05) before and after treatment in the two groups. After treatment, the differences of VEGF, VEGFR and MVD in the two groups were statistically significant (p<0.05). The difference of clinical efficacy between the two groups was statistically significant (P<0.05). The difference of adverse reactions between the two groups was statistically significant(P<0.05).The difference of the risk of recurrence of the two groups was statistical-ly significant(P<0.05),and the difference of the immunophenotype of the two groups was statistically signifi-cant (P<0.05). The recurrence of the two groups was compared,and the differences in risk,immune classifi-cation and recurrence were statistically significant(all P<0.05).Conclusions:The short term clinical efficacy of the BCH-2003 regimen is better than the CCLG-2008 scheme in the treatment of children with TEL-AML1 fusion gene positive acute lymphoblastic leukemia. However,the incidence of adverse reactions and the severi-ty of relapse in the CCLG-2008 regimen were better than that of the BCH-2003 regimen.关键词
BCH-2003方案/CCLG-2008方案/TEL-AML1融合基因/儿童/急性淋巴细胞白血病Key words
BCH - 2003/CCLG - 2008/Tel-aml1 fusion gene/Children/Acute lympho-cytic leukemia
